(Total Views: 415)
Posted On: 01/19/2020 2:20:03 PM
Post# of 153988
AT the at the J.P. Morgan Healthcare Conference O’Day (GILD CEO):
“This has been billed as the coming-out party for Gilead’s strategy, and I’d like to not disappoint in that regard,” he joked to open the company’s Monday presentation, adding that he knows the question on everyone’s mind is, “What’s Gilead going to buy?"
“don’t get me wrong,” noted, adding, “I think we need to think about multiple approaches here.”
While the “vast majority of deals will still be earlier stage by definition,” investors should “rest assured” that Gilead is working to supplement its late-stage portfolio through M&A, too. As it does, it’ll be looking for targets that fit into its core areas of viral diseases, inflammatory diseases, fibrotic diseases and oncology, with a particular focus on immuno-modulatory drugs.
From Dicknson (GILD CFO): expect a “regular cadence of partnership,” including small and medium deals. And the company will be pursuing outright buys.
No comments
“This has been billed as the coming-out party for Gilead’s strategy, and I’d like to not disappoint in that regard,” he joked to open the company’s Monday presentation, adding that he knows the question on everyone’s mind is, “What’s Gilead going to buy?"
“don’t get me wrong,” noted, adding, “I think we need to think about multiple approaches here.”
While the “vast majority of deals will still be earlier stage by definition,” investors should “rest assured” that Gilead is working to supplement its late-stage portfolio through M&A, too. As it does, it’ll be looking for targets that fit into its core areas of viral diseases, inflammatory diseases, fibrotic diseases and oncology, with a particular focus on immuno-modulatory drugs.
From Dicknson (GILD CFO): expect a “regular cadence of partnership,” including small and medium deals. And the company will be pursuing outright buys.
No comments
(1)
(0)
